natgillin/translations-raw huggingface dataset:
In the first study, Quinsair was shown to be better than placebo at improving the patients’ forced expiratory volume in one second (FEV1), adjusted for the patient’s age, height and sex.
U prvom ispitivanju dokazano je da Quinsair djeluje bolje od placeba u poboljšanju u forsiranog izdisajnog volumena u jednoj sekundi (FEV1) s obzirom na dob, visinu i spol ispitanika.
In the first study, RoActemra was more effective than placebo in treating rheumatoid arthritis: after 6 months of treatment with RoActemra, 61% of patients responded to treatment compared with 32% on placebo.
U prvom ispitivanju lijek RoActemra bio je učinkovitiji od placeba u liječenju reumatoidnog artritisa: nakon šest mjeseci terapije lijekom RoActemra 61 % bolesnika odgovorilo je na terapiju, za razliku od 32 % bolesnika koji su odgovorili na placebo.
in the first study, Stocrin in combination with lamivudine and zidovudine or with indinavir (other antiviral medicines) was compared with the combination of indinavir, lamivudine and zidovudine; the second study compared Stocrin in combination with nelfinavir and two other antiviral medicines with the same combination without Stocrin; the third study compared adding Stocrin or placebo (a dummy treatment) to a combination of antiviral medicines that included indinavir and two other antiviral medicines, in patients who had already been receiving treatment for HIV infection.
u prvom je ispitivanju Stocrin u kombinaciji s lamivudinom i zidovudinom ili s indinavirom (drugim antivirusnim lijekovima) uspoređen s kombinacijom indinavira, lamivudina i zidovudina; u drugom je ispitivanju Stocrin u kombinaciji s nelfinavirom i druga dva antivirotika uspoređen s istom kombinacijom bez Stocrina; u trećem je ispitivanju uspoređeno dodavanje lijeka Stocrin ili placeba (lažnog liječenja) u kombinaciju antivirotika koji su uključivali indinavir i druga dva antivirotika u bolesnika koji su već primali terapiju protiv infekcije HIV-om.
in the first study, Sustiva in combination with lamivudine and zidovudine or with indinavir (other antiviral medicines) was compared with the combination of indinavir, lamivudine and zidovudine; the second study compared Sustiva in combination with nelfinavir and two other antiviral medicines with the same combination without Sustiva; the third study compared adding Sustiva or placebo (a dummy treatment) to a combination of antiviral medicines that included indinavir and two other antiviral medicines, in patients who had already been receiving treatment for HIV infection.
u prvom je ispitivanju lijek Sustiva u kombinaciji s lamivudinom i zidovudinom ili s indinavirom (drugim antivirusnim lijekovima) uspoređen s kombinacijom indinavira, lamivudina i zidovudina; u drugom je ispitivanju lijek Sustiva u kombinaciji s nelfinavirom i druga dva antivirotika uspoređen s istom kombinacijom bez lijeka Sustiva; u trećem je ispitivanju uspoređeno dodavanje lijeka Sustiva ili placeba (liječenja bez djelatne tvari) u kombinaciju antivirotika koji su uključivali indinavir i druga dva antivirotika u bolesnika koji su već primali terapiju protiv infekcije HIV-om.
In the first study, the main measure of effectiveness was the number of patients whose platelet count had increased to at least 50,000 cells per microlitre after six weeks.
U prvom ispitivanju glavno mjerilo djelotvornosti bio je broj bolesnika kod kojih se broj trombocita povećao na najmanje 50 000/µl nakon šest tjedana.
In the first study, the patients had an average of 0.08 serious infections per year.
U prvom ispitivanju bolesnici su imali u prosjeku 0,08 ozbiljnih infekcija godišnje.
In the first study, the patients taking Esbriet had a smaller reduction in FVC after 72 weeks than the patients taking placebo.
U prvom ispitivanju, bolesnici koji su uzimali Esbriet imali su manje smanjenje u FVC-u nakon 72 tjedna u odnosu na bolesnike koji su uzimali placebo.
In the first study, type A resistant patients (A-non responders) were randomised to receive placebo or 10,000 U of NeuroBloc and in the second, type A toxin responsive patients (A-responders) were randomised to receive placebo, 5000 U or 10,000 U of toxin.
U prvom ispitivanju bolesnici rezistentni na tip A (bez odgovora na A) bili su randomizirani u skupinu koja je primala placebo ili u skupinu koja je primala 10 000 U NeuroBloca, a u drugom ispitivanju, bolesnici s odgovorom na toksin tipa A (s odgovorom na A) bili su randomizirani u skupine koje su primale placebo, 5000 U ili 10 000 U toksina.
In the first two studies, a total of 614 patients were given either Invega or placebo.
U prva dva ispitivanja, ukupno 614 bolesnika primilo je lijek Invega ili placebo.
In the first two studies, the number of relapses per year among patients treated with Gilenya was around half the number seen in patients given placebo.
U prvim dvama ispitivanjima, broj relapsa godišnje u bolesnika liječenih lijekom Gilenya bio je upola manji od broja relapsa zabilježenih u bolesnika koji su primali placebo.
In the five surgeries that occurred during the study, Nuwiq was rated as excellent in preventing bleeding episodes for four surgeries and as moderate to prevent bleeding during one surgical intervention.
U pet kirurških zahvata tijekom ispitivanja Nuwiq je ocijenjen kao izvrstan u sprječavanju epizoda krvarenja za četiri kirurška zahvata i kao umjeren za sprječavanje krvarenja tijekom jedne kirurške intervencije.
In the fixed weekly interval arm, subjects received ALPROLIX for routine prophylaxis starting at 50 IU/kg.
U skupini liječenoj u fiksnom tjednom intervalu, ispitanici su primali ALPROLIX za rutinsku profilaksu, počevši s dozom od 50 IU/kg.
In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab treated patients, HR = 0.89, 97.5% CI = [0.73; 1.08]; p-value = 0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs.
U podskupini bolesnika liječenih protokolom FOLFOX medijan preživljenja bez progresije bolesti iznosio je 8,6 mjeseci u bolesnika koji su primali placebo, a 9,4 mjeseca u bolesnika liječenih bevacizumabom: omjer hazarda (engl.
In the follow-up of the study evaluating the 2-dose and 3-dose primary vaccination schedules, the persistence of antibodies at 36-46 months of age was demonstrated in subjects that had received a 2-dose primary series followed by a booster dose with at least 83.7% of subjects remaining seropositive for vaccine serotypes and the cross-reactive serotype 19A. In subjects that had received a 3-dose primary series followed by a booster dose, at least 96.5% of the subjects remained seropositive for vaccine serotypes and 86.4% for serotype 19A. After a single dose of Synflorix, administered during the 4th year of life, as a challenge dose, the fold increase in ELISA antibody GMCs and OPA GMTs, pre to post vaccination, was similar in 2-dose primed subjects to that in 3-dose primed subjects.
U razdoblju praćenja nakon ispitivanja koje je ocjenjivalo rasporede primovakcinacije od 2 doze odnosno 3 doze, dokazana je perzistencija protutijela u ispitanika u dobi od 36-46 mjeseci koji su primarno cijepljeni s 2 doze i potom primili dozu docjepljivanja pri čemu je barem 83,7% ispitanika ostalo seropozitivno na serotipove sadržane u cjepivu i na ukriženo reaktivni serotip 19A. U ispitanika koji su primarno cijepljeni s 3 doze i potom primili dozu docjepljivanja, najmanje 96,5% ispitanika je ostalo seropozitivno na serotipove sadržane u cjepivu i 86,4% na serotip 19A. Nakon jedne doze cjepiva Synflorix, primijenjene tijekom četvrte godine života kao provokacijska doza (engl. challenge dose), višestruko povećanje GMC-a protutijela mjerenih ELISA testom i OPA GMT-a prije i nakon cijepljenja bilo je slično u ispitanika primarno cijepljenih s dvije i u ispitanika primarno cijepljenih s tri doze.
In the following 16 weeks, all patients received Ilaris every eight weeks.
Tijekom narednih 16 tjedana svi su bolesnici primali Ilaris svakih osam tjedana.
In the following cases, Zevalin use is not recommended since its safety and efficacy have not been established:
U sljedećim se slučajevima Zevalin ne preporučuje jer sigurnost i djelotvornost lijeka nisu utvrđene:
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests) :
Liječenje Vaše šećerne bolesti može zahtijevati posebnu pozornost (na primjer prilagodbu doze inzulina, pretrage krvi i urina) u sljedećim situacijama:
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):
Liječenje Vaše šećerne bolesti može zahtijevati posebnu pozornost (na primjer prilagodbu doze inzulina, pretrage krvi i mokraće) u sljedećim situacijama:
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):
Liječenje Vaše šećerne bolesti može zahtijevati posebnu pozornost (na primjer prilagodbu doze inzulina, pretrage krvi i urina) u sljedećim situacijama:
In the following situations, the management of your diabetes may require a lot of care:
Liječenje Vaše šećerne bolesti može zahtijevati posebnu pozornost u sljedećim situacijama:
In the following situations, the management of your diabetes may require extra care (e.g. urine and blood tests):
Liječenje Vaše šećerne bolesti može zahtijevati posebnu pozornost (npr. pretrage mokraće i krvi) u sljedećim situacijama:
In the following situations, the management of your diabetes may require extra care:
Liječenje šećerne bolesti može zahtijevati posebnu pozornost u sljedećim situacijama:
In the following table adverse reactions are listed by system organ class and MedDRA preferred term.
U sljedećoj tablici nuspojave su navedene prema klasifikaciji organskih sustava i MedDRA preporučenim izrazima.
In the four main studies, Tygacil was as effective as the comparator antibiotics.
U četiri glavna ispitivanja Tygacil je bio jednako djelotvoran kao i usporedni antibiotici.
In the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
U 4 placebom kontrolirane studije omjeri rizika ukupnog preživljenja su bili između 1,25 i 2,47 u korist kontrolne skupine.
In the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
U četiri placebo kontrolirana ispitivanja, omjer hazarda za ukupno preživljenje varirao je između 1,25 i 2,47 u korist kontrolne skupine.
In the fourth study in adults who had not responded to lamivudine treatment, Viread was effective when given alone: 89% of patients taking Viread had a viral level below 400 copies/ml after 96 weeks of treatment, compared with 86% of patients taking the combination treatment of Viread and emtricitabine.
U četvrtom ispitivanju u odraslih osoba koje nisu odgovorile na liječenje lamivudinom, Viread je bio učinkovitiji ako se uzimao sam: 89% bolesnika koji su uzimali Viread imalo je razinu virusa manju od 400 kopija/ml nakon 96 tjedana liječenja u usporedbi s 86% bolesnika koji su uzimali kombinirano liječenje lijekom Viread i emtricitabinom.
In the fourth study in patients with the R117H mutation, no difference was seen between placebo and Kalydeco for children aged 6 years and above.
U četvrtom ispitivanju u bolesnika s mutacijom R117H nisu zabilježene razlike između placeba i lijeka Kalydeco u djece od šest godina i starije.
In the fourth study patients were encouraged to attempt sexual intercourse approximately 15 minutes post-dosing, to assess the onset of the erectogenic effect of avanafil, taken on an as needed basis, at 100 and 200 mg dose.
U četvrtom ispitivanju se bolesnike poticalo da pokušaju spolni odnos otprilike 15 minuta nakon uzimanja doze, kako bi se procijenio početak erektogenog učinka avanafila uzetog prema potrebi, u dozi od 100 i 200 mg.
In the fourth study, in lung cancer patients who had not responded to previous chemotherapy, the patients taking Tarceva survived for an average of 6.7 months, compared with 4.7 months for the patients taking placebo.
U četvrtom ispitivanju, na bolesnicima s rakom pluća koji nisu pozitivno reagirali na prethodnu kemoterapiju, bolesnici koji su uzimali lijek Tarceva živjeli su još u prosjeku 6,7 mjeseci u usporedbi s bolesnicima koji su uzimali placebo koji su u prosjeku živjeli još 4,7 mjeseci.
In the fourth study, Orencia in combination with methotrexate was compared with Orencia alone and methotrexate alone in 351 adults who had not been treated with methotrexate (or with any so-called biologic agents such as TNF alpha blockers) in the past, but may have been on other medicines for management of rheumatoid arthritis.
U četvrtom ispitivanju lijek Orencia je u kombinaciji s metotreksatom uspoređen samo s lijekom Orencia i samo s metotreksatom u 351 odrasle osobe koje prethodno nisu bile liječene metotreksatom (niti bilo kojim drugim takozvanim biološkim tvarima poput TNF alfa blokatora), ali su mnogi od njih liječeni drugim lijekovima protiv reumatoidnog artritisa.
In the fourth study, previously treated patients with wild-type RAS receiving Vectibix in combination with FOLFIRI lived for 16.2 months compared with 13.9 months in patients receiving FOLFIRI alone.
U četvrtom ispitivanju prethodno liječeni bolesnici s divljim tipom gena RAS koji su primali Vectibix u kombinaciji s FOLFIRI, živjeli su 16,2 mjeseci u usporedbi s 13,9 mjeseci u bolesnika koji su primali samo FOLFIRI.
In the fourth study, the average reduction with Bydureon was 1.5 points after 26 weeks, compared with an average reduction of 1.3 points with insulin glargine.
U četvrtome je ispitivanju prosječno smanjenje iznosilo 1,5 bodova nakon liječenja lijekom Bydureon u trajanju od 26 tjedana, u usporedbi s prosječnim smanjenjem od 1,3 boda nakon liječenja inzulinom glarginom.
In the fourth study, which included 498 patients who had an inadequate response to TNF blockers, patients receiving RoActemra with methotrexate were around 9 times more likely to respond than those receiving placebo with methotrexate.
U četvrtom ispitivanju, kojim je bilo obuhvaćeno 498 bolesnika koji nisu primjereno odgovorili na inhibitore TNF-a, bolesnici koji su primali lijek RoActemra s metotreksatom imali su otprilike devet puta više izgleda za odgovor u odnosu na one koji su primali placebo s metotreksatom.
In the fourth trial, approximately 800 patients (aged ≥ 2 years) received 0.1% tacrolimus ointment intermittently or continuously in an open-label, long-term safety study for up to four years, with 300 patients receiving treatment for at least three years and 79 patients receiving treatment for a minimum of 42 months.
U četvrtom je ispitivanju približno 800 bolesnika (starosti ≥ 2 godine) intermitentno ili kontinuirano primalo mast s 0,1% takrolimusa u otvorenom, dugotrajnom ispitivanju sigurnosti u trajanju do četiri godine, s time da je 300 bolesnika primalo liječenje najmanje tri godine, a 79 bolesnika najmanje 42 mjeseca.
In the fourth trial, approximately 800 patients (aged ≥ 2 years) received 0.1% tacrolimus ointment intermittently or continuously in an open-label, long-term safety study for up to four years, with 300 patients receiving treatment for at least three years and 79 patients receiving treatment for a minimum of 42 months.
U četvrtom je ispitivanju približno 800 bolesnika (starosti ≥ 2godine) intermitentno ili kontinuirano primalo mast s 0,1% takrolimusa u otvorenom, dugotrajnom ispitivanju sigurnosti u trajanju do četiri godine, s time da je 300 bolesnika primalo liječenje najmanje tri godine, a 79 bolesnika najmanje 42 mjeseca.
In the further course of treatment your requirement for analgesic therapy may change.
Tijekom daljnjeg liječenja Vaše se potrebe za analgetskom terapijom mogu promijeniti.
In the future if rabbits are exposed to rabbit haemorrhagic disease type 2 virus, the immune system will be able to produce antibodies more quickly.
Ako će kunići u budućnosti biti izloženi virusu tipa 2 koji uzrokuje hemoragičnu bolest kunića, njihov imunosni sustav moći će brže proizvesti protutijela.
In the future, if the
Ubuduće ako se životinje izlože ovim
In the future, if the animals are exposed to Muscovy duck parvovirus, the immune system will
U buduće ako se životinje izlože parvovirusu mošusne patke, imunosni sustav će moći brže odgovoriti.
In the future, if the animals are exposed to PCV2, the immune system will be able to produce antibodies more quickly.
U buduće, ako je životinja izložena PCV2, imunosni sustav moći će brže proizvesti antitijela.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these virus strains.
Reproduction is authorised provided the source is acknowledged. će imunosni sustav biti u stanju brže stvarati protutijela nakon izloženosti bilo kojem od ovih sojeva virusa.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these viruses.
Prilikom budućeg izlaganja tim virusima imunološki će sustav moći brže proizvoditi protutijela.
In the FUTURE-4 study including 13 neonates with PPHN treated with bosentan 2 mg/kg twice daily for less than 10 days (range 0.5–10.0 days) there were no cases of liver aminotransferases ≥ 3  ULN during treatment but one case of hepatitis occurred 3 days after the end of bosentan treatment.
U FUTURE-4 studiji koja je uključila 13 novorođenčadi s PPHN-om liječene bosentanom u dozi od 2 mg/kg dvaput dnevno kraće od 10 dana (raspon 0,5-10,0 dana) nije bilo slučajeva s porastom razine jetrenih aminotransferaza  3 x GGN tijekom liječenja, ali se pojavio jedan slučaj hepatitisa 3 dana nakon završetka liječenja bosentanom.
In the FUTURE-4 study including 13 neonates with PPHN treated with bosentan 2 mg/kg twice daily for less than 10 days (range 0.5–10.0 days) there were no cases of liver aminotransferases ≥ 3  ULN during treatment, but one case of hepatitis occurred 3 days after the end of bosentan treatment.
U FUTURE-4 studiji koja je uključila 13 novorođenčadi s PPHN-om liječene bosentanom u dozi od 2 mg/kg dvaput dnevno kraće od 10 dana (raspon 0,5-10,0 dana) nije bilo slučajeva s porastom razine jetrenih aminotransferaza  3 x GGN tijekom liječenja, ali se pojavio jedan slučaj hepatitisa 3 dana nakon završetka liječenja bosentanom.
In the genotype 1b replicon, the activity of paritaprevir was reduced 76- and 159-and 337- fold by D168A, D168H, D168V, and D168Y respectively.
U replikonu genotipa 1b, aktivnost paritaprevira je smanjeno 76, 159 odnosno 337 puta supstitucijom D168A, D168H, D168V odnosno D168Y.
In the GESTURE Study, secukinumab was superior to placebo at Week 16 (33.3% for 300 mg, 22.1% for 150 mg, and 1.5% for placebo) as assessed by significant improvement of ppIGA 0 or 1 response (“clear” or “almost clear”) for patients with moderate to severe palmoplantar plaque psoriasis.
U GESTURE ispitivanju, sekukinumab je bio superioran nad placebom u 16. tjednu (33,3% za 300 mg, 22,1% za 150 mg, i 1,5% za placebo) što je pokazano značajnim poboljšanjem ppIGA 0 ili 1 odgovora (“čista” ili “gotovo čista”) za bolesnike s umjerenom do teškom palmoplantarnom plak psorijazom.
In the GLP toxicity studies, with the exception of irreversible peripheral axonal toxicity (observed only in monkeys at  10 mg/kg) and reproductive organ toxicity (observed only in rats at 60 mg/kg), partially or completely reversible dose dependent toxicities were identified in both animal models.
U ispitivanjima toksičnosti u skladu s dobrom laboratorijskom praksom u oba su životinjska modela primijećene djelomično ili potpuno reverzibilne toksičnosti ovisne o dozi, uz izuzetak ireverzibilne toksičnosti za aksone perifernih neurona (primijećene samo kod majmuna pri dozama od ≥ 10 mg/kg) i toksičnosti za reproduktivne organe (primijećene samo kod štakora kod doze od 60 mg/kg).
In the group that kept on receiving the GLP-1 agonist, it fell from 7.7% to 7.4%.
U skupini koja je i dalje primala agonist GLP-1, ta je vrijednost pala sa 7,7 % na 7,4 %.
In the group using insulin degludec it fell from 8.8% to 8.0%.
U komparatorskoj se grupi spustila s 8,8 % na 8,0 %.
In the gut, blockage of the tubes from the pancreas and the liver as well as the production of abnormal digestive juices slows down the digestion of food and causes poor growth.
Začepljenje kanala iz gušterače i jetre, kao i proizvodnja abnormalnih probavnih tekućina usporavaju probavu hrane i uzrok su premalog rasta.
In the gut, blockage of the tubes from the pancreas slows down the digestion of food and causes poor growth.
Začepljenje kanala iz gušterače dovodi do usporavanja probave hrane u probavnom sustavu i sprečava rast.
In the HALT-C study, patients with chronic hepatitis C and advanced fibrosis or cirrhosis who were non-responders to previous treatment with interferon alfa or pegylated interferon alfa monotherapy or in combination therapy with ribavirin were treated with Pegasys 180 mcg/week and ribavirin 1000/1200 mg daily.
U ispitivanju HALT-C, bolesnici s kroničnim hepatitisom C i uznapredovalom fibrozom ili cirozom koji nisu odgovorili na ranije liječenje interferonom alfa ili pegiliranim interferonom alfa primijenjenim kao monoterapija ili u kombinaciji s ribavirinom, bili su liječeni lijekom Pegasys u dozi od 180 mikrograma/tjedan i ribavirinom u dozi od 1000/1200 mg dnevno.
In the HBeAg positive subjects randomised to emtricitabine plus tenofovir disoproxil fumarate, 13 of 68 subjects (19%) experienced HBeAg loss, and 7 of 68 subjects (10%) experienced anti-HBe seroconversion through week 240.
Među HBeAg-pozitivnih ispitanika randomiziranih za emtricitabin i tenofovirdizoproksilfumarat, 13 od 68 (19%) ispitanika imalo je nestanak HBeAg, a 7 od 68 (10%) ispitanika imalo je anti-HBe serokonverziju kroz 240 tjedana.
In the HD-Dex arm, median PFS time was 8.0 weeks (95% CI: 7.0, 9.0); the estimated 26-week event-free survival rate was 12.15% (±3.63%).
U skupini koja je primala HD-Dex, medijan PFS-a bio je 8,0 tjedana (95% CI: 7,0; 9,0) uz EFS od 12,15% (±3,63%) na 26 tjedana.
In the hip and knee studies, there was some evidence that the 220 mg dose may be more effective than the 150 mg dose.
U ispitivanjima u vezi s kukovima i koljenima bilo je dokaza da doza od 220 mg može biti djelotvornija od doze od 150 mg.
In the historical controls, most children did not experience similar improvements in their joints or gain in height over a comparable period of time.
U povijesnim kontrolama, većina djece nije iskusila slična poboljšanja u svojim zglobovima ili narasla u visinu tijekom usporedivog razdoblja.
In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when ribavirin is administered.
U HIV-pozitivnih bolesnika koji primaju NRTI liječnici moraju pažljivo kontrolirati pokazatelje mitohondijske toksičnosti i laktacidoze nakon uvođenja terapije ribavirinom.
In the HORIZON – Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving Aclasta and placebo, respectively.
U HORIZON-PFT (Pivotal Fracture Trial) ispitivanju (vidjeti dio 5.1) ukupna incidencija atrijske fibrilacije bila je 2,5% (96 od 3862) i 1,9% (75 od 3852) u bolesnika koji su primali Aclastu, odnosno placebo.
In the HORIZON – Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively.
U ispitivanju HORIZON – (Pivotal Fracture Trial [PFT]) (vidjeti dio 5.1), ukupna incidencija atrijske febrilacije iznosila je 2,5% (96 od 3862) u bolesnika koji su primali zoledronatnu kiselinu i 1,9% (75 od 3852) u onih koji su primali placebo.